Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

Breast Cancer Research and Treatment

Volumn 121, Issue 1, 2010, Pages 121-131

  Barrios, Carlos H ^a   Liu, Mei Ching ^b   Lee, Soo Chin ^c   Vanlemmens, Laurence ^d   Ferrero, Jean Marc ^e   Tabei, Toshio ^f   Pivot, Xavier ^g   Iwata, Hiroji ^h   Aogi, Kenjiro ⁱ   Lugo Quintana, Roberto ^j   Harbeck, Nadia ^k,l   Brickman, Marla J ^m   Zhang, Ke ⁿ   Kern, Kenneth A ⁿ   Martin, Miguel ^o  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d Oscar Lambret Centre   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f SAITAMA CANCER CENTER   (Japan)

^g UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^h AICHI CANCER CENTER HOSPITAL   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^j Hospital Christus Muguerza Del Parque   (Mexico)

^k UNIVERSITY OF COLOGNE   (Germany)

^l TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^m Pfizer Ltd   (United States)

ⁿ PFIZER INC   (United States)

^o HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

more..

Author keywords

Advanced breast cancer; Capecitabine; Sunitinib malate; Tyrosine kinase inhibitor

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SUNITINIB; TAXANE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; LIVER DYSFUNCTION; LIVER FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPTIC SHOCK; SIDE EFFECT; STOMATITIS; SUBDURAL HEMATOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENES, ERBB-2; HUMANS; INDOLES; KAPLAN-MEIERS ESTIMATE; PYRROLES;

EID: 77951296573     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0788-0     Document Type: Article

References (23)

1. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 783 792 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D 11248153 (Pubitemid 32222155)
2. Blackwell KL, Burstein HJ, Sledge GW et al (2009) Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. In: San Antonio Breast Cancer symposium (Abstract 61)
3. F Cardoso A Di Leo C Lohrisch C Bernard F Ferreira MJ Piccart 2002 Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13 2 197 207 10.1093/annonc/mdf101 1:STN:280:DC%2BD387ltl2htw%3D%3D 11885995 (Pubitemid 34704970)
4. Roche Pharmaceuticals (2006) XELODA (capecitabine) prescribing information, Nutley, NJ
5. S Banerjee M Dowsett A Ashworth LA Martin 2007 Mechanisms of disease: angiogenesis and the management of breast cancer Nat Clin Pract Oncol 4 9 536 550 10.1038/ncponc0905 1:CAS:528:DC%2BD2sXps12msrs%3D 17728712 (Pubitemid 47351464)
6. J Paulsson T Sjöblom P Micke, et al. 2009 Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer Am J Pathol 175 1 334 341 10.2353/ajpath.2009.081030 19498003
7. K Miller M Wang J Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2666 2676 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D 18160686
8. Miles DW, Chan A, Romieu G et al (2009) Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). Presented at the 32nd annual San Antonio Breast Cancer symposium, San Antonio, TX, USA, December 9-13 (Oral presentation; abstract 41)
9. Robert NJ, Dieras V, Glaspy J et al (2009) RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27:15s (Abstr 1005)
10. MA Cobleigh VK Langmuir GW Sledge, et al. 2003 A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 5 Suppl 16 117 124 10.1053/j.seminoncol.2003.08.013 1:CAS:528:DC%2BD3sXhtVSjtrvF 14613032
11. DB Mendel AD Laird X Xin, et al. 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 1 327 337 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D 12538485
12. TJ Abrams LB Lee LJ Murray NK Pryer JM Cherrington 2003 SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 5 471 478 1:CAS:528: DC%2BD3sXkvVersbw%3D 12748309
13. Pfizer Inc (2009) SUTENT (sunitinib) prescribing information, New York, NY
14. HJ Burstein AD Elias HS Rugo, et al. 2008 Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 11 1810 1816 10.1200/JCO.2007.14.5375 1:CAS:528: DC%2BD1cXmsFemsb8%3D 18347007
15. B Escudier J Roigas S Gillessen, et al. 2009 Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 25 4068 4075 10.1200/JCO.2008.20.5476 1:CAS:528:DC%2BD1MXhtF2jtL3J 19652072
16. Barrios CH, Hernandez-Barajas D, Brown MP et al (2009) Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Presented at the joint 15th congress of the European CanCer Organisation and 34th congress of the European Society for Medical Oncology, Berlin, Germany, September 20-24 (Poster presentation; Abstract P-7122)
17. S George JY Blay PG Casali, et al. 2009 Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure Eur J Cancer 45 11 1959 1968 10.1016/j.ejca.2009.02.011 1:CAS:528:DC%2BD1MXotFCjs7Y%3D 19282169
18. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 3 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437 (Pubitemid 30099779)
19. KD Miller LI Chap FA Holmes, et al. 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 4 792 799 10.1200/JCO.2005.05.098 1:CAS:528:DC%2BD2MXitVKitrk%3D 15681523 (Pubitemid 46224178)
20. Jennison T, Turnbull BW (1999) Group sequential methods with applications to clinical trials, Chapman & Hall/CRC Interdisciplinary Statistics Series. CRC Press LLC, Boca Raton
21. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2009) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol Dec 5 (Epub ahead of print)
22. G Bianchi S Loibl C Zamagni, et al. 2009 Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer Anticancer Drugs 20 7 616 624 10.1097/CAD.0b013e32832b2ea0 1:CAS:528: DC%2BD1MXotFCgtr4%3D 19739318
23. Baselga J, Grupo Español de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos, Roché H et al (2009) SOLTI-0701: A multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). San Antonio Breast Cancer symposium (Abstract 45)